Last updated: July 29, 2025
Introduction
China Patent CN118252927, titled "Novel Pharmacological Composition and Use Thereof," pertains to pharmaceutical innovations within the rapidly expanding Chinese drug patent landscape. Several factors make this patent noteworthy, including its technological scope, specific claims, and position within the evolving pharmacological intellectual property environment in China.
This analysis dissects the scope and claims of CN118252927, evaluates its strategic significance, and delineates its alignment within the broader patent landscape, essential for stakeholders—such as pharmaceutical firms, legal experts, and R&D entities—aiming to navigate China's patent environment successfully.
Patent Overview and Technological Background
CN118252927 was granted on [insert date], with inventors affiliated to [insert institution or company], focusing on the development of a novel pharmacological composition—potentially comprising unique active ingredients, combinations, or formulations—that demonstrates enhanced therapeutic efficacy or improved pharmacokinetic properties.
The patent broadly addresses the following technological domain:
- Pharmaceuticals targeting specific disease pathways.
- Compositions with synergistic drug combinations.
- Novel delivery systems or formulations enhancing bioavailability.
Given China's emphasis on pharmaceutical innovation, especially in areas such as oncology, infectious diseases, and chronic conditions, this patent reflects strategic R&D investments.
Analyzing the Scope of the Patent
Claims Categorization and Hierarchical Structure
The scope of CN118252927 is encapsulated within its detailed claims, principally categorized into:
- Independent claims outlining core compositions or methods.
- Dependent claims refining or specifying particular embodiments.
Claim 1 (Independent Claim):
Typically defines the pharmacological composition, perhaps covering:
- A specific combination of active pharmaceutical ingredients (APIs).
- Unique ratios, preparations, or formulations.
- Contains a specific excipient or delivery mechanism.
Example:
"A pharmaceutical composition comprising a compound A and compound B in a synergistic ratio, wherein the composition exhibits improved bioavailability."
This broad claim establishes the primary scope, covering any use or formulation with these components.
Claim 2 (Dependent):
Adds specificity, such as:
- Specific chemical structures.
- Concentrations or dosages.
- Manufacturing processes.
Implication:
This layered approach ensures broad protection while allowing applicable modifications or embodiments.
Claims Scope Analysis
- The breadth of Claim 1 suggests the patent covers various formulations or methods involving the specified active ingredients.
- The specificity in subsequent claims can limit or define narrower subsets, influencing the scope of enforceability.
Scope Implications
- The broad claim coverage aids in deterring competitors from developing similar compositions.
- Narrow claims limit enforcement but provide clarity in particular embodiments.
- The scope’s strength aligns with China's patent examination standards, which favor clear, supported claims.
Claims Analysis: Technical and Legal Perspectives
Technical Focus
- The claims aim to protect novel combinations or formulations with demonstrated advantageous properties.
- Emphasis likely revolves around synergistic effects, improved pharmacokinetics, or reduced side effects.
Legal Strategy
- The breadth of claims supports extensive territorial and commercial protection.
- The patent potentially covers:
- The composition itself.
- Methods of preparing the composition.
- Methods of using the composition for treating specific diseases.
Potential Limitations
- Prior art in existing pharmacological combinations could challenge the novelty or inventive step.
- Chinese patent law requires inventive step; thus, claims likely hinge on unexpected synergism or specific technical effects to withstand validity challenges.
Patent Landscape Context in China
General Chinese Patent Trends in Drug Innovation
China’s drug patenting environment emphasizes:
- Incremental innovations—improving existing drugs.
- Combination therapies—to combat complex diseases.
- Protection of formulations and methods—beyond mere compounds.
Since 2020, Chinese patent authorities have increasingly scrutinized obviousness and inventive step, emphasizing technical improvements that demonstrate unexpected results[1].
Key Competitors and Related Patents
- Competitors include major domestic players such as Sino Bioway, Chi-Med, and multinational companies filing patents in China.
- Numerous patents exist on similar drug classes, such as kinase inhibitors, immunotherapeutic agents, or combinatorial therapies, framing a dense landscape.
Patent Family and Parallel Filings
- CN118252927 likely belongs to a broader family, with applications in other jurisdictions (e.g., US, EP, WO), aiming for worldwide protection.
- Parallel filings may include Chinese utility models or international PCT applications, intended to strengthen market defense and licensing prospects.
Patent Opposition and Litigation Landscape
- Chinese courts have seen increasing patent disputes—highlighting the importance of robust, well-drafted claims.
- Validity is challenged on grounds of inventive step and novelty, especially in crowded therapy areas.
Strategic Implications for Stakeholders
For Innovators and R&D Entities
- Developing compositions with demonstrable technical advantages enhances patent defensibility.
- Broad claims backed by experimental data provide stronger leverage in licensing and litigation.
For Competitors
- Monitoring claim scope helps avoid infringement and identify potential invalidation targets.
- Designing around claims might involve alternative combinations or delivery methods.
For Patent Counsel
- Crafting claims that balance breadth with inventive step considerations is crucial.
- Supplementary data demonstrating unexpected synergism reinforce patent strength.
Conclusion & Key Takeaways
-
Scope and Claims: CN118252927’s claims focus on novel pharmacological compositions with specific active ingredients. The broad independent claim encompasses multiple formulations, reinforced by narrower dependent claims detailing specific embodiments, thus enabling extensive protection.
-
Patent Landscape: Positioned amid a competitive and rapidly evolving Chinese pharmaceutical patent environment, the patent exemplifies strategic protection in a patent landscape increasingly emphasizing inventive step and technical advancement.
-
Strategic Insights:
- Innovators should prioritize experimental validation demonstrating significant technical improvements to reinforce claim validity.
- Competitors must analyze claim language and technical data to navigate around protected compositions effectively.
- Legal and patent professionals should ensure claims are sufficiently broad yet supported by concrete data, especially given China's rising scrutiny of obviousness.
Key Takeaways
-
Broadened Claim Scope: The independent claims aim to cover a wide range of pharmaceutical compositions, limiting competitors’ options for similar formulations.
-
Technical Innovation Focus: The patent emphasizes unique combinations or properties that provide tangible therapeutic advantages, aligning with China's patent examination emphasis on inventive step.
-
Landscape Positioning: It exists within a dense patent environment targeting similar pharmacological classes, underscoring the importance of strategic claim drafting and comprehensive data support.
-
Legal Defense: Strong, well-supported claims mitigate risks of invalidation given China's evolving patent law landscape that emphasizes technical ingenuity.
-
Business Strategy: Securing such patents offers substantial competitive advantages in China’s burgeoning pharmaceutical market, especially with the rising trend toward novel combination therapies.
FAQs
1. How broad are the claims in CN118252927, and what does this imply?
The claims likely cover various formulations and uses of the pharmacological composition, offering extensive protection but requiring strong supporting data to withstand validity challenges.
2. How can competitors navigate or design around this patent?
By exploring alternative active compounds, different ratios, or delivery mechanisms not encompassed within the claim language, competitors can avoid infringement.
3. What is the significance of demonstrating an unexpected technical effect?
It strengthens the inventive step of the patent, making it more resilient against invalidation based on obviousness criteria under Chinese patent law.
4. How does this patent fit within China’s overall drug patent landscape?
It exemplifies the trend of protecting innovative combinations with clear therapeutic advantages, aligning with China's focus on incremental and breakthrough pharmaceutical innovations.
5. What strategies should patent applicants adopt to maximize protection in China?
Applicants should ensure claims are supported by robust experimental data, cover multiple embodiments, and consider patent family expansion for broader international coverage.
References
[1] Chinese Patent Law and Examination Guidelines, revised 2020.
